Aurobindo Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Telangana. The USFDA has classified the said facility as Voluntary Action Indicated (VAI) and this inspection is now closed.
The USFDA had conducted an inspection of the said facility from January 28 to February 10, 2026 and issued a ‘Form 483’ with 09 observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1836.60 |
| Dr. Reddys Lab | 1311.90 |
| Cipla | 1369.40 |
| Zydus Lifesciences | 941.85 |
| Lupin | 2457.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: